Multiomics Market
Multiomics Market Forecasts to 2032 – Global Analysis By Type (Genomics, Transcriptomics, Proteomics, Metabolomics, Epigenomics, Lipidomics and Microbiomics), Product & Service (Instruments, Consumables, Software & Analytics Platforms and Services), Technology (Single-Cell Multiomics, Bulk Multiomics and Spatial Multiomics), Application, End User and By Geography
According to Stratistics MRC, the Global Multiomics Market is accounted for $3.2 billion in 2025 and is expected to reach $9.1 billion by 2032 growing at a CAGR of 15.9% during the forecast period. Multiomics is the integrated analysis of multiple “omics” data sets genomics, proteomics, transcriptomics, metabolomics, and more to gain a comprehensive understanding of biological systems. By aggregating diverse molecular layers, multiomics enables precise disease profiling, biomarker discovery, and targeted therapeutic development. It enhances data-driven decision-making across sectors such as precision medicine, diagnostics, and drug development.
Market Dynamics:
Driver:
Rise in precision medicine & personalized therapies
Multiomics provides the comprehensive molecular insights necessary to enable this personalized approach by integrating genomic, transcriptomic, proteomic, and metabolomic data to create detailed patient profiles. This integrated analysis allows healthcare professionals to identify specific disease mechanisms, predict treatment responses, and develop targeted therapeutic interventions. Furthermore, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions has intensified the demand for personalized treatment solutions, driving significant investments from both private and public sectors in multiomics research and development.
Restraint:
Lack of standardized analytical pipelines
The absence of standardized frameworks for data integration and interpretation continues to pose significant challenges for the multiomics market, limiting widespread adoption and reproducibility of research findings. Different omics datasets possess varying formats and structures, making seamless integration extremely complex and time-consuming for researchers. Additionally, the complexity of developing robust computational pipelines for multiomics analysis, combined with the high costs associated with specialized equipment and highly skilled personnel, creates substantial barriers for smaller research organizations and limits market penetration.
Opportunity:
Integration of AI/ML in multiomics data analysis
AI algorithms excel at integrating and analyzing vast datasets from various omics fields, enabling faster identification of disease subtypes, drug targets, and biomarkers while accelerating drug discovery processes. Cloud computing platforms are transforming how researchers handle large and complex multiomics datasets, providing scalable and cost-effective solutions for data storage and analysis. Advanced AI-driven predictive models can identify individuals at risk for specific diseases and predict treatment responses, facilitating the development of more effective personalized therapies and improving diagnostic accuracy across multiple healthcare applications.
Threat:
Risk of data breach or cybersecurity incidents
Stringent regulatory requirements such as GDPR in the European Union and HIPAA in the United States impose complex compliance obligations for collecting, storing, and sharing personal genomic and molecular data. The increasing interconnectedness of research networks and cloud-based platforms expands the attack surface for potential cyber threats. Data breaches involving multiomics information could have far-reaching consequences, including identity theft, discrimination, and loss of patient trust.
Covid-19 Impact:
The COVID-19 pandemic significantly accelerated multiomics research and applications, demonstrating the technology's critical role in understanding viral pathogenesis and host immune responses. Researchers utilized integrated multiomics approaches to profile plasma proteins, metabolites, and cellular transcripts from COVID-19 patients, revealing comprehensive molecular landscapes that single omics approaches could not capture. These studies identified 84 potentially active compounds for COVID-19 treatment and led to the discovery of six candidate drugs through computational analysis. Additionally, the pandemic highlighted multiomics' superior ability to detect viral entry pathways and complement system activation, providing crucial insights for therapeutic intervention strategies.
The bulk multiomics segment is expected to be the largest during the forecast period
The bulk multiomics segment is expected to account for the largest market share during the forecast period due to its widespread adoption in large-scale population studies, drug discovery initiatives, and comprehensive disease profiling applications. This approach remains the standard in multiomics workflows because of its cost-effectiveness compared to single-cell alternatives and the availability of well-established analytical tools and protocols. Additionally, research institutions and pharmaceutical companies prefer bulk multiomics for conducting extensive genomic studies and biomarker discovery programs, as it provides reliable results across diverse patient populations.
The precision medicine segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the precision medicine segment is predicted to witness the highest growth rate, driven by multiomics data's unique ability to customize treatments based on individual patient molecular characteristics, resulting in more effective and personalized healthcare outcomes. This approach combines genomics, proteomics, metabolomics, and other molecular data layers to provide deeper understanding of disease mechanisms and identify specific therapeutic targets by analyzing root causes of diseases and predicting patient responses to different treatments. Furthermore, the growing recognition that traditional one-size-fits-all treatment approaches are inadequate for complex diseases continues to drive investment and research.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to its robust research infrastructure, substantial investments in healthcare and biotechnology R&D, and strong support from both government and private sector funding initiatives. The region benefits from the presence of major life science companies, including Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which drive continuous innovation in multiomics approaches and technologies. The FDA's supportive regulatory environment for biomarker-guided drug development, combined with the region's advanced healthcare infrastructure and focus on personalized medicine, reinforces North America's dominant position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by increasing investments in life sciences research, a rapidly expanding number of biotechnology startups, and substantial improvements in healthcare infrastructure, particularly in key markets like China, Japan, and India. Government initiatives across the region actively promote biotechnology growth through comprehensive policies such as India's National Development Programmes and Sustainable Development Goals, which specifically support biotech development and biomanufacturing capabilities. Moreover, the region's growing prevalence of various diseases has intensified focus on novel drug discovery applications, with countries like China emerging as leaders in multiomics research through companies like BGI Group and substantial investments in genomics research and precision medicine initiatives. The combination of supportive regulatory environments, increasing healthcare awareness, and strategic government backing positions Asia Pacific as the fastest-growing regional market
Key players in the market
Some of the key players in Multiomics Market include 10x Genomics, Agilent Technologies, Becton, Dickinson and Company (BD), BGI Genomics, Bio-Rad Laboratories, Bio-Techne Corporation, Bruker, Danaher Corporation, Illumina, Mission Bio, NanoString Technologies, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Revvity, QIAGEN, Roche, Standard BioTools, Shimadzu Corporation, Thermo Fisher Scientific, and Human Longevity, Inc.
Key Developments:
In June 2025, Illumina, Inc. announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
In August 2024, Agilent announced a cooperation agreement with Sangon Biotech to advance nucleic acid research, with particular focus on promoting development in synthetic biology and multi-omics.
In January 2024, BD announced collaboration with Hamilton to develop automated applications and robotics-compatible reagent kits to enable greater standardization in large-scale single-cell multiomics experiments.
Types Covered:
• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Epigenomics
• Lipidomics
• Microbiomics
Product & Services:
• Instruments
• Consumables
• Software & Analytics Platforms
• Services
Technologies Covered:
• Single-Cell Multiomics
• Bulk Multiomics
• Spatial Multiomics
Applications Covered:
• Drug Discovery & Development
• Precision Medicine
• Biomarker Discovery
• Clinical Diagnostics
• Agrigenomics
• Personalized Nutrition
• Environmental Research
• Microbiome Analysis
• Other Applications
End Users Covered:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Clinics
• CROs & CDMOs
• Diagnostic Laboratories
• Agrigenomics Companies
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Multiomics Market, By Type
5.1 Introduction
5.2 Genomics
5.3 Transcriptomics
5.4 Proteomics
5.5 Metabolomics
5.6 Epigenomics
5.7 Lipidomics
5.8 Microbiomics
6 Global Multiomics Market, By Product & Service
6.1 Introduction
6.2 Instruments
6.2.1 Sequencing Instruments
6.2.2 Mass Spectrometers
6.2.3 Chromatography Systems
6.2.4 Microarrays
6.3 Consumables
6.3.1 Reagents & Kits
6.3.2 Assay Kits
6.3.3 Sample Preparation Kits
6.4 Software & Analytics Platforms
6.4.1 Data Integration & Visualization Tools
6.4.2 AI/ML Platforms
6.5 Services
6.5.1 Multiomics Data Analysis
6.5.2 Custom Services
6.5.3 Contract Research Services
7 Global Multiomics Market, By Technology
7.1 Introduction
7.2 Single-Cell Multiomics
7.3 Bulk Multiomics
7.4 Spatial Multiomics
8 Global Multiomics Market, By Application
8.1 Introduction
8.2 Drug Discovery & Development
8.3 Precision Medicine
8.4 Biomarker Discovery
8.5 Clinical Diagnostics
8.6 Agrigenomics
8.7 Personalized Nutrition
8.8 Environmental Research
8.9 Microbiome Analysis
8.10 Other Applications
9 Global Multiomics Market, By End User
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Academic & Research Institutes
9.4 Hospitals & Clinics
9.5 CROs & CDMOs
9.6 Diagnostic Laboratories
9.7 Agrigenomics Companies
9.8 Other End Users
10 Global Multiomics Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 10x Genomics
12.2 Agilent Technologies
12.3 Becton, Dickinson and Company (BD)
12.4 BGI Genomics
12.5 Bio-Rad Laboratories
12.6 Bio-Techne Corporation
12.7 Bruker
12.8 Danaher Corporation
12.9 Illumina
12.10 Mission Bio
12.11 NanoString Technologies
12.12 Oxford Nanopore Technologies
12.13 Pacific Biosciences (PacBio)
12.14 Revvity
12.15 QIAGEN
12.16 Roche
12.17 Standard BioTools
12.18 Shimadzu Corporation
12.19 Thermo Fisher Scientific
12.20 Human Longevity, Inc.
List of Tables
1 Global Multiomics Market Outlook, By Region (2024-2032) ($MN)
2 Global Multiomics Market Outlook, By Type (2024-2032) ($MN)
3 Global Multiomics Market Outlook, By Genomics (2024-2032) ($MN)
4 Global Multiomics Market Outlook, By Transcriptomics (2024-2032) ($MN)
5 Global Multiomics Market Outlook, By Proteomics (2024-2032) ($MN)
6 Global Multiomics Market Outlook, By Metabolomics (2024-2032) ($MN)
7 Global Multiomics Market Outlook, By Epigenomics (2024-2032) ($MN)
8 Global Multiomics Market Outlook, By Lipidomics (2024-2032) ($MN)
9 Global Multiomics Market Outlook, By Microbiomics (2024-2032) ($MN)
10 Global Multiomics Market Outlook, By Product & Service (2024-2032) ($MN)
11 Global Multiomics Market Outlook, By Instruments (2024-2032) ($MN)
12 Global Multiomics Market Outlook, By Sequencing Instruments (2024-2032) ($MN)
13 Global Multiomics Market Outlook, By Mass Spectrometers (2024-2032) ($MN)
14 Global Multiomics Market Outlook, By Chromatography Systems (2024-2032) ($MN)
15 Global Multiomics Market Outlook, By Microarrays (2024-2032) ($MN)
16 Global Multiomics Market Outlook, By Consumables (2024-2032) ($MN)
17 Global Multiomics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
18 Global Multiomics Market Outlook, By Assay Kits (2024-2032) ($MN)
19 Global Multiomics Market Outlook, By Sample Preparation Kits (2024-2032) ($MN)
20 Global Multiomics Market Outlook, By Software & Analytics Platforms (2024-2032) ($MN)
21 Global Multiomics Market Outlook, By Data Integration & Visualization Tools (2024-2032) ($MN)
22 Global Multiomics Market Outlook, By AI/ML Platforms (2024-2032) ($MN)
23 Global Multiomics Market Outlook, By Services (2024-2032) ($MN)
24 Global Multiomics Market Outlook, By Multiomics Data Analysis (2024-2032) ($MN)
25 Global Multiomics Market Outlook, By Custom Services (2024-2032) ($MN)
26 Global Multiomics Market Outlook, By Contract Research Services (2024-2032) ($MN)
27 Global Multiomics Market Outlook, By Technology (2024-2032) ($MN)
28 Global Multiomics Market Outlook, By Single-Cell Multiomics (2024-2032) ($MN)
29 Global Multiomics Market Outlook, By Bulk Multiomics (2024-2032) ($MN)
30 Global Multiomics Market Outlook, By Spatial Multiomics (2024-2032) ($MN)
31 Global Multiomics Market Outlook, By Application (2024-2032) ($MN)
32 Global Multiomics Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
33 Global Multiomics Market Outlook, By Precision Medicine (2024-2032) ($MN)
34 Global Multiomics Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
35 Global Multiomics Market Outlook, By Clinical Diagnostics (2024-2032) ($MN)
36 Global Multiomics Market Outlook, By Agrigenomics (2024-2032) ($MN)
37 Global Multiomics Market Outlook, By Personalized Nutrition (2024-2032) ($MN)
38 Global Multiomics Market Outlook, By Environmental Research (2024-2032) ($MN)
39 Global Multiomics Market Outlook, By Microbiome Analysis (2024-2032) ($MN)
40 Global Multiomics Market Outlook, By Other Applications (2024-2032) ($MN)
41 Global Multiomics Market Outlook, By End User (2024-2032) ($MN)
42 Global Multiomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
43 Global Multiomics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
44 Global Multiomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
45 Global Multiomics Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
46 Global Multiomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
47 Global Multiomics Market Outlook, By Agrigenomics Companies (2024-2032) ($MN)
48 Global Multiomics Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
